Genetic Technologies hits U.S. firms with patent infringement
Wednesday, 17 February, 2010
Genetic Technologies has filed a patent infringement suit against nine U.S. biotechnology companies, including Bechman Coulter and Monsanto.
The patent at the centre of the suit refers to non-coding DNA technologies that Genetic Technologies claims are being used by the biotech firms without license.
The counter-parties in the suit are Beckman Coulter, Orchid Cellmark, Gen-Probe, Interleukin Genetics, Molecular Pathology Laboratory Network, Monsanto, PIC USA, Sunrise Medical Laboratories and Pioneer Hi-Bred International.
The non-coding DNA technology in question is already licensed to 39 other companies.
In 2008 Genetic Technologies stirred up controversy by demanding several Australian labs cease performing a test for the breast cancer genes BRCA1 and BRCA2 for which the company held an exclusive license. Genetic Technologies later withdrew the threat and allowed testing for the genes to continue.
The company has been successful in other patent infringement suits, such as in 2005 against Applera Corporation (now ABI Biosystems).
Inhaled form of blood thinner treats serious COVID infections
Heparin has traditionally been injected and used to treat blood clots, but the new study tested...
Next-gen therapies could treat high-grade gliomas
Government funding will enable researchers to test a suite of next-generation therapies they have...
Bacteriophage cocktail to combat superbugs
Entelli-02 is a five-phage cocktail designed specifically to target Enterobacter cloacae...
